OZEMPIC
oral semaglutide · Novo Nordisk Pharmaceutical Industries, LP · TABLET
Open FDA's page for this record- Product NDC
- 0169-1704
- Generic name
- oral semaglutide
- Labeler name
- Novo Nordisk Pharmaceutical Industries, LP
- Brand name
- OZEMPIC
- Finished
- true
- Listing expiration date
- 20271231
- Marketing category
- NDA
- Dosage form
- TABLET
- SPL ID
- 6834044a-22f1-4f35-b846-b3448ee84c16
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing start date
- 20260427
- Product ID
- 0169-1704_6834044a-22f1-4f35-b846-b3448ee84c16
- Application number
- NDA213051
- Brand name base
- OZEMPIC
- Active ingredients
- Name
- SEMAGLUTIDE
- Strength
- 4 mg/1
- Packaging
- Package NDC
- 0169-1704-30
- Description
- 30 TABLET in 1 BOTTLE, PLASTIC (0169-1704-30)
- Marketing start date
- 20260427
- Sample
- false
- Route
- ORAL
- Pharm class
- GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
- Harmonized identifiers (openFDA)
- Manufacturer name
- Novo Nordisk Pharmaceutical Industries, LP
- RxCUI
- 2200644, 2200650, 2200652, 2200654, 2200656, 2200658, 2707547, 2707549, 2707551, 2707553, 2707555, 2707557, 2736944, 2736946, 2736948
- SPL set ID
- 27f15fac-7d98-4114-a2ec-92494a91da98
- Is original packager
- true
- Nui
- N0000178480, M0160181, N0000020058
- Pharm class epc
- GLP-1 Receptor Agonist [EPC]
- Pharm class cs
- Glucagon-Like Peptide 1 [CS]
- Pharm class moa
- Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
- UNII
- 53AXN4NNHX